Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) Tax Provisions (2019 - 2024)

Historic Tax Provisions for C4 Therapeutics (CCCC) over the last 4 years, with Q4 2024 value amounting to $131000.0.

  • C4 Therapeutics' Tax Provisions fell 5270.76% to $131000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $131000.0, marking a year-over-year decrease of 8976.56%. This contributed to the annual value of $131000.0 for FY2024, which is 8976.56% down from last year.
  • As of Q4 2024, C4 Therapeutics' Tax Provisions stood at $131000.0, which was down 5270.76% from $277000.0 recorded in Q4 2023.
  • C4 Therapeutics' 5-year Tax Provisions high stood at $1.0 million for Q3 2023, and its period low was -$168000.0 during Q2 2020.
  • Moreover, its 3-year median value for Tax Provisions was -$124000.0 (2020), whereas its average is $112142.9.
  • The largest annual percentage gain for C4 Therapeutics' Tax Provisions in the last 5 years was 2916.67% (2020), contrasted with its biggest fall of 12569.23% (2020).
  • C4 Therapeutics' Tax Provisions (Quarter) stood at -$124000.0 in 2020, then surged by 323.39% to $277000.0 in 2023, then plummeted by 52.71% to $131000.0 in 2024.
  • Its Tax Provisions was $131000.0 in Q4 2024, compared to $277000.0 in Q4 2023 and $1.0 million in Q3 2023.